An interventional study of novel oral anticoagulant for 30 days and novel oral anticoagulant for 24 hour in Atrial Fibrillation, sponsored by Yonsei University. Status unknown at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2019-02-15.
Sponsored by Yonsei University · Not applicable, Interventional, and Treatment
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding, thromboembolic, vascular complications, Re-admission and increased in the length of hospital stay during the 30-day post-radiofrequency catheter ablation(RFCA) period among patients who interrupt NOAc 24hours before ablation and patients who stop NOAC in the morning of the procedure.
3,957 studies on the registry are indexed under Atrial Fibrillation; 933 are open to participants now.
This study's planned enrollment of 433 is above the median of 145 across 2,437 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Yonsei University is the lead sponsor of 1,410 studies on the registry; 235 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
Drug: novel oral anticoagulant for 30 days
The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
Drug: novel oral anticoagulant for 24 hour
novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
incidence of major bleeding complications
Bleeding complication is assessed by physical examination or laboratory measurement
Time frame: during 30 days post-AF ablation.
incidence of thromboembolism
thromboembolism is diagnosed by both clinical situations and image studies combined.
Time frame: during 30 days post-AF ablation.
incidence of minor bleeding
Time frame: during 30 days post-AF ablation.
Re-admission rate related procedure
Time frame: during 30 days post-AF ablation.
length of hospital stay
Time frame: during 30 days post-AF ablation.
incidence of vascular complications
vascular complication is diagnosed by both clinical situations and image studies combined.
Time frame: during 30 days post-AF ablation.
The record gives a start of Jun 2015, a primary completion of Jun 2019 and a completion of Jun 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.